Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
In the last 90 days, Atea Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 126 institutions reported holding it in 13F filings for Q3 2026, worth $307.4M in total; no superinvestor holds it.
Holders of 5% or more of AVIR
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Atea Pharmaceuticals, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%12.0M shares | +3.40 ppfrom 11.60% | Feb 8, 202110 filings | May 6, 2026 | SEC |
| Sommadossi Jean-Pierre | 13G/A | 11.00%9.08M shares | +0.90 ppfrom 10.10% | Feb 10, 20216 filings | Nov 13, 2026 | SEC |
| BML Investment Partners, L.P. | 13G | 9.90%7.81M shares | +1.40 ppfrom 8.50% | Oct 2, 20235 filings | Feb 9, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.10%6.08M shares | – | Apr 23, 20251 filing | Apr 23, 2025 | SEC |
| Tang Capital Management LLC | 13G | 6.00%4.81M shares | New | Oct 6, 20261 filing | Oct 6, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
52 Schedule 13D and 13G filings on Atea Pharmaceuticals, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 20264:43 PM ET | Sommadossi Jean-Pierreand 1 other | 13G/A | 11.00%9.08M shares | +0.90 ppfrom 10.10% | Sep 30, 2026 | SEC |
| Oct 6, 20266:20 PM ET | Tang Capital Management LLCand 5 others | 13G | 6.00%4.81M shares | New | Oct 6, 2026 | SEC |
| May 6, 202611:00 AM ET | FMR LLCand 1 other | 13G/A | 15.00%12.0M shares | +3.40 ppfrom 11.60% | Mar 31, 2026 | SEC |
| Mar 26, 20264:11 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Feb 9, 20262:02 PM ET | BML Investment Partners, L.P.and 1 other | 13G | 9.90%7.81M shares | +1.40 ppfrom 8.50% | Dec 31, 2025 | SEC |
| Dec 5, 20252:03 PM ET | FMR LLCand 1 other | 13G/A | 11.60%9.10M shares | +4.90 ppfrom 6.70% | Nov 28, 2025 | SEC |
| Aug 6, 202511:51 AM ET | FMR LLCand 1 other | 13G/A | 6.70%5.72M shares | – | Jun 30, 2025 | SEC |
| May 14, 20256:21 PM ET | Sommadossi Jean-Pierreand 1 other | 13G/A | 10.10%8.88M shares | – | Mar 31, 2025 | SEC |
| Apr 23, 20258:14 PM ET | BlackRock, Inc. | 13G/A | 7.10%6.08M shares | – | Mar 31, 2025 | SEC |
| Apr 17, 202512:23 PM ET | Radoff Bradley Louisand 9 others | 13D/A | 4.00%3.38M shares | +0.40 ppfrom 3.60%Below 5% | Apr 16, 2025 | SEC |
| Mar 21, 202511:58 AM ET | Radoff Bradley Louisand 9 others | 13D/A | 3.60%3.11M shares | +0.30 ppfrom 3.30%Below 5% | Mar 20, 2025 | SEC |
| Mar 4, 20259:27 AM ET | Radoff Bradley Louisand 5 others | 13D | 3.30%2.82M shares | NewBelow 5% | Feb 27, 2025 | SEC |
| Feb 14, 202512:47 PM ET | EcoR1 Capital, LLCand 2 others | 13G/A | 4.00%3.34M shares | –Below 5% | Dec 31, 2024 | SEC |
| Dec 16, 20249:50 AM ET | BML Investment Partners, L.P.and 1 other | 13D | 8.50%7.22M shares | – | Dec 13, 2024 | SEC |
| Nov 14, 2024 | EcoR1 Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Nov 12, 2024 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | EcoR1 Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | EcoR1 Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | EcoR1 Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2024 | Sommadossi Jean-Pierre | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2024 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2024 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 7, 2024 | BML Investment Partners, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 7, 2024 | BML Investment Partners, L.P. | 13GOld format | – | – | – | SEC |
| Jan 24, 20249:46 AM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Nov 28, 2023 | Tang Capital Partners LP | 13D/AOld format | – | – | – | SEC |
| Nov 7, 20233:33 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Oct 2, 2023 | BML Investment Partners, L.P. | 13GOld format | – | New | – | SEC |
| Sep 11, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| May 22, 2023 | Tang Capital Partners LP | 13DOld format | – | New | – | SEC |
| Feb 10, 2023 | Sommadossi Jean-Pierre | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2023 | EcoR1 Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | Vanguard Group Inc | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Jan 24, 20231:56 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2022 | Morningside Venture Investments Ltd | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Ra Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | Cormorant Asset Management, LP | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Sommadossi Jean-Pierre | 13G/AOld format | – | – | – | SEC |
| Feb 9, 2022 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 4, 20224:12 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Dec 10, 2021 | EcoR1 Capital, LLC | 13GOld format | – | New | – | SEC |
| Sep 24, 2021 | Bain Capital Life Sciences Fund II, L.P. | 13D/AOld format | – | – | – | SEC |
| Sep 3, 2021 | Bain Capital Life Sciences Fund II, L.P. | 13D/AOld format | – | – | – | SEC |
| Apr 7, 2021 | Ra Capital Management, L.P. | 13G/AOld format | – | – | – | SEC |
| Mar 10, 2021 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Ra Capital Management, L.P. | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Morningside Venture Investments Ltd | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Cormorant Asset Management, LP | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
16 notices from officers, directors and other affiliates planning to sell Atea Pharmaceuticals, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 20265:04 PM ET | Bruce PolskyDirector | 18.3K | $72.1K | Nov 18, 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Nov 17, 20264:37 PM ET | Bruce PolskyDirector | 8.72K | $35.2K | Nov 17, 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Nov 17, 20264:23 PM ET | Bruno LucidiDirector | 6.74K | $27.2K | Nov 17, 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Nov 16, 20264:12 PM ET | Bruce PolskyDirector | 14.3K | $60.8K | Nov 16, 2026 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| Dec 10, 20245:17 PM ET | Franklin BergerLead Independent Director | 359.6K | $1.02M | Dec 10, 2024 | J.P. Morgan Securities LLC | SEC |
| Sep 19, 20244:22 PM ET | JPM Partners LLCAffiliate | 1.84K | $7.37K | Sep 19, 202410b5-1 | UBS Financial Services Inc. | SEC |
| Sep 18, 20244:09 PM ET | JPM Partners LLCAffiliate | 22.2K | $89.5K | Sep 18, 202410b5-1 | UBS Financial Services Inc. | SEC |
| Sep 17, 20244:16 PM ET | JPM Partners LLCAffiliate | 33.9K | $137.3K | Sep 17, 202410b5-1 | UBS Financial Services Inc. | SEC |
| Jun 20, 20245:32 PM ET | Polsky BruceDirector | 17.5K | $68.8K | Jun 20, 2024 | MORGAN STANLEY SMITH BARNEY LLC EXECUTIVE SERVICES | SEC |
| Jun 5, 20244:04 PM ET | JPM Partners LLCAffiliate | 1.01K | $4.02K | Jun 5, 202410b5-1 | UBS Financial Services Inc. | SEC |
| Feb 1, 20244:15 PM ET | Wayne FosterEVP, Chief Accounting Officer | 14.3K | $58.2K | Feb 1, 202410b5-1 | Morgan Stanley | SEC |
| Feb 1, 20244:15 PM ET | Jean-Pierre SommadossiPresident, CEO, and Chairman | 65.5K | $266.5K | Feb 1, 202410b5-1 | Morgan Stanley | SEC |
| Feb 1, 20244:15 PM ET | Janet MJ HammondChief Development Officer | 16.1K | $65.6K | Feb 1, 202410b5-1 | Morgan Stanley | SEC |
| Feb 1, 20244:15 PM ET | John VavrickaChief Commercial Officer | 13.6K | $55.2K | Feb 1, 202410b5-1 | Morgan Stanley | SEC |
| Feb 1, 20244:15 PM ET | Maria Arantxa HorgaChief Medical Officer | 18.2K | $74.2K | Feb 1, 202410b5-1 | Morgan Stanley | SEC |
| Feb 1, 20244:15 PM ET | Andrea CorcoranCFO, EVP, Legal and Secretary | 18.2K | $74.1K | Feb 1, 202410b5-1 | Morgan Stanley | SEC |